本帖最后由 老马 于 2012-1-13 21:20 编辑
* G& ~6 g. W; |3 @% O w
5 R) R! m) R* D9 i爱必妥和阿瓦斯丁的比较
* m/ L/ J* q, w% p+ c! N
$ \8 l' d/ T) Phttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/, t3 y; n& Z6 |- e
\& E% b6 f0 ^9 \5 b
3 y" \1 g# J/ ]& L( O2 ^
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
5 i" ]) s0 C4 g# [% @- O3 d1 }==================================================
% D1 n+ U4 h- {4 }$ nOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)% X3 t( s& X [$ p
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
7 U: u6 h+ S# ^' J! v6 r# {Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
5 o2 ]6 z6 m9 {" g9 D2 O) j. T
|